PMID- 11562775
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20190605
IS  - 1107-3756 (Print)
IS  - 1107-3756 (Linking)
VI  - 8
IP  - 4
DP  - 2001 Oct
TI  - Detection and quantification of human herpesvirus 6 genomes using bronchoalveolar 
      lavage fluid in immunocompromised patients with interstitial pneumonia.
PG  - 379-83
AB  - Human herpesviruses have been recognized as a pathogen involved in interstitial 
      pneumonia (IP), especially in immunocompromised patients. So far, little is known 
      about involvement of human herpesvirus 6 (HHV-6) in systemic respiratory tract 
      disease. Currently, routine diagnostic tests for HHV-6 are inefficient for HHV-6 
      reactivation, therefore, we established a rapid quantification system of HHV-6 
      using real-time PCR in order to determine the possible role of human HHV-6 
      reactivation in immunocompromised patients showing IP. Bronchoalveolar lavage 
      fluid (BALF) specimens were obtained from 84 consecutively treated patients with 
      interstitial lung diseases (ILD) including various types of IP. First, we 
      determined the viral burden in BALF and peripheral blood obtained from healthy 
      volunteers. In healthy volunteers, the prevalence of HHV-6 in BALF was higher 
      (4/12, 33.3%) than in peripheral blood (8/53, 15.1%), ranging from 0 to 101.65 
      HHV-6 genome copies per 1 microg of DNA. Among 84 patients with ILD analyzed, the 
      prevalence of HHV-6 in BALF was 27.4% (23/84), ranging from 0 to 103.87 copies 
      per 1 microg of DNA. Three specimens obtained from patients with collagen 
      vascular disease, 2 from Hodgkin's disease, and 1 with sarcoidosis had high level 
      of HHV-6 viral DNA, while none of the patients with idiopathic IP showed 
      elevation of HHV-6 (more than 102) in BALF. Our results suggest that measurement 
      of HHV-6 genomes in BALF using real-time PCR may be useful in management of the 
      care of respiratory complications in immunocompromised patients.
FAU - Nagate, A
AU  - Nagate A
AD  - First Department of Internal Medicine, Tokyo Medical University, Tokyo 113-8510, 
      Japan.
FAU - Ohyashiki, J H
AU  - Ohyashiki JH
FAU - Kasuga, I
AU  - Kasuga I
FAU - Minemura, K
AU  - Minemura K
FAU - Abe, K
AU  - Abe K
FAU - Yamamoto, K
AU  - Yamamoto K
FAU - Ohyashiki, K
AU  - Ohyashiki K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
RN  - 0 (DNA, Viral)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Bronchoalveolar Lavage Fluid/*virology
MH  - DNA/genetics
MH  - DNA, Viral/genetics
MH  - Female
MH  - *Genome, Viral
MH  - Herpesvirus 6, Human/*genetics/growth & development
MH  - Humans
MH  - *Immunocompromised Host
MH  - Lung Diseases/virology
MH  - Lung Diseases, Interstitial/*virology
MH  - Male
MH  - Middle Aged
MH  - Polymerase Chain Reaction
MH  - Retrospective Studies
MH  - Roseolovirus Infections/*virology
MH  - Sarcoidosis/virology
MH  - Virus Activation
EDAT- 2001/09/20 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/09/20 10:00
PHST- 2001/09/20 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/09/20 10:00 [entrez]
AID - 10.3892/ijmm.8.4.379 [doi]
PST - ppublish
SO  - Int J Mol Med. 2001 Oct;8(4):379-83. doi: 10.3892/ijmm.8.4.379.